John H. Ford
Deep value, special situations

Senesco's Extreme Undervaluation Provides Multi-Bagger Opportunity

(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

Senesco (SNTI.OB) is one of the most undervalued biotech companies I have ever analyzed. The company has developed a new oncology drug that has outperformed the best oncology drug on the market. But what I really like about this investment is that even with excellent clinical trial results, near-term catalysts, insider buying, and a $75 billion total addressable market, Senesco is trading at a 90% discount to its peers. This is market irrationality at its best. Opportunities of this magnitude are rare.

Senesco's mispricing will not last

Senesco's mispricing is so dramatic that the following price targets appear unrealistic. But when conducting

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details